Filling the need for trusted information on national health issues…

Trending on kff Medicare & Medicaid at 50 Individual Market Medicaid Expansion

Kaiser Daily Global Health Policy ReportIntellectual Property and Trade Search Results « » The Henry J. Kaiser Family Foundation

Intellectual Property and Trade

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Market-Shaping Techniques Can Help Reach Global Health Goals

Devex: The promise of collective action in shaping global health markets Joe Wilson, market access adviser in the Center for Accelerating Innovation and Impact at USAID “…In a recent report, ‘Healthy Markets for Global Health: A Market-Shaping Primer,’ USAID’s Center for Accelerating Innovation and Impact draws on experiences across health…

Indonesia To Issue Compulsory Licenses For HIV, Hepatitis B Drugs Still Under Patent

“The Indonesian government hopes to implement one of the largest ever examples of ‘compulsory licensing,’ which will enable the generic manufacture of drugs still under patent,” IRIN reports. “Under the World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (TRIPS), countries can override patents for public health purposes by…

India’s Supreme Court Rules Against Novartis AG In ‘Landmark’ Patent Case

“India’s Supreme Court on Monday rejected drug maker Novartis AG’s attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines,” the Associated Press reports. “Novartis had…

Reuters Examines Implications Of India’s Novartis Patent Ruling For Big Pharma

Reuters examines the implications of India’s Supreme Court ruling to overturn a patent on Novartis’s cancer treatment Glivec for the pharmaceutical industry in India and across the developing world. “Stung by a landmark patent defeat, Western drug makers will be wary about launching new products in India, but they cannot…

Five Japanese Drug Makers Form PPP To Accelerate Development Of Drugs, Vaccines For Infectious Diseases

“Five Japanese pharmaceutical giants are teaming up with the Bill & Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries,” GENNews reports (4/8). “The Global Health Innovative Technology (GHIT) fund will see Takeda, Astellas, Daiichi-Sankyo, Eisai and Shionogi partner with [the] non-profit…

Pharmaceutical Industry To Push For Stricter Compulsory Licensing Of Patented Drugs At U.S. Trade Representative Meeting

Wall Street Journal: Pharma Narrowly Defines When Compulsory Licenses Should be Used “As the U.S. Trade Representative holds a hearing [Tuesday] to discuss how countries protect intellectual property, the pharmaceutical industry hopes to persuade the agency that countries should only be allowed to grant licenses to companies to make low-cost…

U.S. Trade Policies Threaten To Undermine Successful Global Health Programs

The Hill: U.S. trade policy could raise drug prices, at home and abroad Rep. Jan Schakowsky (D-Ill.) and Peter Maybarduk, director of Public Citizen’s Global Access to Medicines program “…[With the creation of PEPFAR, t]he United States put public health needs ahead of pharmaceutical industry profits and made a transformative…

Passage Of ‘Innovation Act’ By Congress Would Harm Drug Development

Roll Call: The Wrong Direction on Patents Todd E. Gillenwater, senior vice president of Public Policy at the California Healthcare Institute “…Poorly conceived and hastily written legislation can stunt innovation, harm the economy, and even cost lives. Unfortunately, this is the case with the recently reintroduced Innovation Act (H.R. 9).…

Critics Question Effectiveness Of Medicines Patent Pool In Improving Access To Drugs

SciDev.Net: Merck’s HIV patent agreement ignites monopoly criticism “Pharma giant Merck has become the latest drug company to share intellectual property rights with a U.N.-backed patent pool for HIV medicines, but critics have told SciDev.Net it is ‘a false solution to a real problem’…” (Kennedy, 3/16).